Topas Therapeutics, based in Hamburg (Germany), has developed a unique technology for the induction of antigen-specific immune tolerance. This new approach has the potential to treat autoimmune diseases, allergies and drug induced immune reactions in a more efficient and safe way. The funds will be used to expand and accelerate the Company’s proprietary tolerance induction platform and to develop its products through proof-of-concept studies. The company is a spin-out from Evotec, a global drug discovery and development partnership company.
- Aktivität: Biopharma company
- Website: topas-therapeutics.com
- Location: Deutschland
- Investititionsjahr: 2016
- Plattform: Health & Care